Upregulation of SATB1 is associated with the development and progression of glioma by Sheng-Hua Chu et al.
Chu et al. Journal of Translational Medicine 2012, 10:149
http://www.translational-medicine.com/content/10/1/149RESEARCH Open AccessUpregulation of SATB1 is associated with the
development and progression of glioma
Sheng-Hua Chu1*, Yan-Bin Ma1, Dong-Fu Feng1, Hong Zhang1, Zhi-An Zhu1, Zhi-Qiang Li2 and Pu-Cha Jiang2Abstract
Background: Special AT-rich sequence-binding protein-1 (SATB1) has been reported to be expressed in several
human cancers and may have malignant potential. This study was aimed at investigating the expression and
potential role of SATB1 in human glioma.
Method: The relationship between SATB1 expression, clinicopathological parameters, Ki67 expression and MGMT
promoter methylation status was evaluated, and the prognostic value of SATB1 expression in patients with gliomas
was analyzed. SATB1-specific shRNA sequences were synthesized, and U251 cells were transfected with SATB1 RNAi
plasmids. Expression of SATB1 mRNA and protein was investigated by RT-PCR and immunofluoresence staining and
western blotting. The expression of c-Met, SLC22A18, caspase-3 and bcl-2 protein was determined by western
blotting. U251 cell growth and adherence was detected by methyl thiazole tetrazolium assay. The apoptosis of
U251 cells was examined with a flow cytometer. The adherence, invasion, and in vitro angiogenesis assays of U251
cells were done. The growth and angiogenesis of SATB1 low expressing U251 cells was measured in an in vivo
xenograft model.
Results: Of 70 tumors, 44 (62.9%) were positive for SATB1 expression. SATB1 expression was significantly associated
with a high histological grade and with poor survival in univariate and multivariate analyses. SATB1 expression was
also positively correlated with Ki67 expression but negatively with MGMT promoter methylation in glioma tissues.
SATB1 shRNA expression vectors could efficiently induce the expression of SLC22A18 protein, increase the caspase-
3 protein, inhibit the expression of SATB1, c-Met and bcl-2 protein, the growth, invasion, metastasis and
angiogenesis of U251 cells, and induce apoptosis in vitro. Furthermore, the tumor growth of U251 cells expressing
SATB1 shRNA were inhibited in vivo, and immunohistochemical analyses of tumor sections revealed a decreased
vessel density in the animals where shRNA against SATB1 were expressed.
Conclusions: SATB1 may have an important role as a positive regulator of glioma development and progression,
and that SATB1 might be a useful molecular marker for predicting the prognosis of glioma.Background
Gliomas are a major class of human intrinsic brain
tumors, which includes well differentiated low grade
astrocytomas, anaplastic astrocytomas and glioblastoma
multiforme, the most malignant brain tumor of adult-
hood. Although resection remains the most effective
treatment for glioma, the high rate of postoperative re-
currence inevitably leads to a poor clinical outcome
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reproduction in any medium, provided the ormolecular pathogenic processes involved in the tumori-
genesis of glioma is therefore critical for the develop-
ment of rational, targeted therapies [3].
Special AT-rich sequence-binding protein 1 (SATB1) is
a cell type-specific nuclear matrix attachment region
(MAR)-binding protein that links specific DNA elements
to its cage-like network [4], which is predominantly
expressed in thymocytes [5]. It facilitates formation of
an open chromatin structure and participates in the
regulation of hundreds of genes. In recent years, a num-
ber of studies have suggested that it plays major roles in
T-cell development, early erythroid differentiation,
homeostasis and response to physiological stimuli [6-8].
In addition to discoveries of these physiological roles,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to its high expression in tumor tissues of a variety of
malignancies, such as breast cancer [9], lymphoma [10],
gastric cancer [11], colorectal cancer and laryngeal can-
cer [12,13], which suggest a crucial role in promoting
tumor growth, invasion and metastasis, and may also
have a potential value of being a candidate for cancer
therapy [14]. In the current study, we sought to deter-
mine the expression and functional role of SATB1 in gli-
omas, in order to define the relationship between
SATB1, tumor behavior and prognosis.
Methods
Patients and specimens
Seventy surgically resected human glioma specimens
were collected at the Department of Neurosurgery,
Zhongnan Hospital of Wuhan University between 2003
and 2005 and the NO.3 People's Hospital Affiliated to
Shanghai Jiao Tong University School of Medicine be-
tween 2005 and 2006. Informed patient consent and
prior approval from the Zhongnan Hospital of Wuhan
University and NO.3 People's Hospital Affiliated to
Shanghai Jiao Tong University School of Medicine Eth-
ics Committees (Ethic approval ZNHWHU0388,
NTPHSHJTUSM045) was obtained before the clinical
materials were used for research purposes. Tissue from
three normal brains was obtained from individuals who
had died in traffic accidents without any prior patho-
logically detectable condition. All experiments on
humans in the present study were performed in compli-
ance with the Helsinki Declaration. The study group
consisted of 54 men and 16 women with a median age
of 45 years (range, 17–76 years). None of these patients
had received radiotherapy or chemotherapy prior to sur-
gery. All tumor specimens were pathologically diagnosed
as glioma. All samples were divided into two subgroups
according to histological types: low grade gliomas
(WHO grades I and II) and high grade gliomas (grades
III and IV). Forty-five patients received focal fractionated
radiotherapy; and 42 patients received postoperative
chemotherapy. Postoperative chemotherapy was adminis-
tered with temozolomide (TMZ) or teniposide (VM-26)
together with semustine (methyl-[N-[2-chloroethyl]-N0-
[4-methylcyclohexyl]- N-nitrosourea] [Me-CCNU]). Of
these 42 patients, 40 also chose to undergo concomitant
focal fractionated radiotherapy. All specimens were stored
at −80°C until analysis.
Cell culture
ECV304 cells and human glioma cell line U251 (Wuhan
University of China) were cultured in RPMI-1640 (Gibco
Life Technologies, Paisley, Scotland, UK) supplemented
with 10% fetal bovine serum 100 μg/ml penicillin, and
100 μg/ml streptomycin. Routine testing confirmed thatthe cells were free of Mycoplasma and viral contami-
nants during the entire study period.
Knock down SATB1 by RNAi in U251 cells
SATB1-specific shRNA sequences were synthesized
according to the one used in Han et al. [15]. and inserted
into the pGCsi-H1/Neo/GFP/siNEGative vector (Genscript),
which coexpresses GFP to allow identification of transfection
efficiency. The SATB1 shRNA sequence was: SATB1-
shRNA 5'-GTCCACCTTGTCTTCTCTC-3'. The non-
specific shRNA sequence was: control-shRNA-GFP
5'-ACGTGACACGTTCGGAGAA-3' [16]. U251 cells were
transiently transfected with SATB1 RNAi plasmids or con-
trol plasmids using an electroporator.
Immunohistochemical analysis
Antigen retrieval was performed in boiling citrate buffer
for 15 minutes. Peroxide blocking was performed with
0.3% peroxide in absolute methanol. The slides were then
incubated with anti-SATB1 polyclonal antibody (diluted
1:100; Sigma, St Louis, MO) or mouse anti-PCNA mono-
clonal antibody (diluted 1:100; Santa Cruz) or anti-Ki67
(diluted 1:20; clone MIB-1, Dako, Denmark) at 4°C over-
night and washed twice with PBS before being incubated
with the secondary antibody (Santa Cruz, CA) at room
temperature for 30 mintes. After washing, sections were
incubated with immunoglobulins conjugated with horse-
radish peroxidase (HRP). Finally, the reaction was devel-
oped with 3, 3'-diaminobenzidine substrate. Tissue
sections were counterstained with hematoxylin or methyl
green [17]. Immunohistochemical staining for CD34 and
microvessel counting of CD34-positive vessels were per-
formed as described previously [18].
The total SATB1 immunostaining score was calcu-
lated as the sum of the percentage positivity of stained
tumor cells and the staining intensity scores. The per-
centage positivity was scored as follows: 0 (< 5%, nega-
tive); 1 (5%-25%, sporadic); 2 (25%-50%, focal); 3
(> 50%, diffuse). The staining intensity was scored as
follows: 0 (no staining); 1 (weakly stained); 2 (moder-
ately stained); 3 (strongly stained). Both the percentage
positivity of cells and the staining intensity were
assessed under double-blind conditions. The final
SATB1 expression score ranged from 0 to 9 and was
calculated as the percentage positivity score × staining
intensity score. The SATB1 expression level was defined
as follows: - (score 0–1); + (score 2–3); ++ (score 4–6);
+++ (score > 6). The Ki67 index was calculated as the
percentage of Ki67-positive cells in five independent
high-magnification (× 200) fields per section [19,20].
DNA extraction and MSP
Briefly, genomic DNA was extracted from tumor tissues
by the digestion with proteinase K using the Genomic
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USA) and 1μg genomic DNA was treated with the
Chemicon CpG WIZ™ DNA Modification Kit (Chemicon
International, Temecula, CA, USA) to convert unmethy-
lated cytosines to uracil, leaving methylated cytosines un-
changed. The modified DNA was diluted in TE buffer.
O(6) -methylguanine-DNA-methyltransferase (MGMT)
promoter methylation analysis was performed by PCR,
using bisulfite-treated DNA as template, with specific pri-
mers for the methylated (unmodified by bisulfite treat-
ment) and unmethylated (bisulfite modified) gene
sequences using the MSP method.4 The MGMT primer
sequences for the unmethylated reaction (UMS sense
5'-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3' and
UMAS antisense 5'-AACTCCACACTCTTCCAAAAA
CAAAACA-3’) were designed to amplify a 93bp prod-
uct [21]. The MGMT primer sequences for the
methylated reaction (MS sense 5'-TTTCGACGTTC
GTAGGTTTTC GC-3' and MAS antisense 5'-G
CACTCTTCCGAAAACGAAACG-3') were designed
to amplify a 81bp product [21]. The results were con-
firmed by repeating the bisulfite treatment and MSP
assays for all samples.
Western blotting analysis
Untransfected U251, control-shRNA-GFP U251 or
SATB1-shRNA U251 cells were washed in ice-cold PBS
and lysed in buffer using standard methods [22]. The fro-
zen samples of glioma and normal brain tissues were
homogenized in a RIPA lysis buffer. Lysates were cleared
by centrifugation (14, 000rpm) at 4°C for 30 minutes. Pro-
tein samples (approximately 40μg) were separated by SDS-
PAGE (15% gel), transferred to PVDF membrane and non-
specific binding sites blocked by incubation in 5% non-fat
milk for 60 minutes. Membranes were incubated overnight
at 4°C with polyclonal anti-SATB1 primary antibody (1:200
dilution; Sigma, St Louis, MO) or anti-c-Met antibody
(1:400 dilution; Santa Cruz, CA) or anti-SLC22A18 anti-
body (1:1,000 dilution; Santa Cruz, CA) or anti-caspase-3
antibody (1:500 dilution; Dako, Glostrap, Denmark) or
anti-bcl-2 antibody (1:300 dilution; Dako, Glostrap, Den-
mark). The membrane was then washed three times with
TBST for 10 minutes and probed with HRP-conjugated
secondary antibody (at 1:2,000 dilution; Dako, Glostrap,
Denmark) for 30 minutes at room temperature. After
being washed three times, the membrane was developed
using an enhanced chemiluminescence system (ECL,
Pierce).
Total RNA isolation and reverse-transcriptase polymerase
chain reaction
Total RNA was extracted from glioma tissues, normal
brains, and U251 cells, using TRIzol (Invitrogen, Carlsbad,
CA) following the manufacturer's instructions. The RTreaction was performed on 2 μg of total RNA using the
SuperScript II First-Strand Synthesis and an oligo(dT)
primer (Invitrogen). The SATB1 primer sequences and
RT-PCR conditions were as previously described (forward
primer 5'-CATTCAAGCTCCTTTCCCTTTC-3' and re-
verse primer 5'-TGGGCTCGTATC AACACC TATC-3')
[23]. The housekeeping gene GAPDH was used as an inter-
nal control for the RT reaction (forward primer
5'-TGGGGAAGGTGAAGGTCG-3' and reverse primer
5'-CTGGAAGATGGTGATGGGA-3'). PCR was per-
formed over 35 cycles at 94°C for 1 minute, at 62°C for 1
minute, and 72°C for 1 minute followed by a final exten-
sion at 72°C for 5 minutes and the PCR products were ana-
lyzed using 2% agarose gels.
Immunofluorescence staining
Cells were harvested on day 2 post-transfection for ana-
lysis, washed once with PBS and fixed with 4% paraformal-
dehyde in PBS for 20 minutes at 4°C. After blocked with
10% goat serum (Dako, Glostrap, Denmark), the cells were
incubated with monoclonal mouse anti-SATB1 (1:50 dilu-
tion; Sigma, St Louis, MO) for 2 hours at 37°C. After three
washes, the cells were incubated with Cy3-conjugated
rabbit anti-mouse secondary antibodies (1:300 dilution;
ICN Cappel, USA) for 1 hour at 37°C and washed three
times with PBS. The stained cells were mounted and ana-
lyzed under fluorescence microscope. DAPI was used to
visualize nuclei.
Measurement of cell growth
Cell proliferation was measured using the methyl thiazole
tetrazolium (MTT) assay [24,25]. Cells were seeded in 24-
well plates at a density of 1 × 104 cells/well and 24 hours
later 200 μl 5 mg/μl MTT (Sigma) in PBS was added to
each well incubated for 4 hours at 37°C and the precipitate
was solubilized in 100 μl 100% dimethylsulfoxide (Sigma)
with shaking for 15 minutes. Absorbance values were
determined using an enzyme-linked immunosorbent assay
reader (Model 318, Shanghai, China) at 540 nm. Each
assay was performed nine times and the results are
expressed as the mean ± SE compared to the control.
Measurement of apoptosis by flow cytometry
U251 cells were harvested on hour 24 and 48 post-
transfection for analysis, After washing with PBS fixed in
70% cold ethanol treated with 10 g/L RNase suspended
and stained with 10 g/L propidium iodine, U251 cells were
stained directly with PI at a concentration of 10 μg/ml and
2% Annexin-V-Fluos (Roche, Basel, Swizerland) in incuba-
tion buffer for 10 minutes. Cells were acquired with the
FACS calibrator (BD) after setting the instrument with the
controls (nontreated, stained cells), after two washes in
PBS. In this experiment, cells with early apoptotic signals,
stained with annexin-V, and cells with late death signals,
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apoptotic cells were analyzed using CellQuest software.
Each assay was performed in triplicate.
Tumor cell adherence to ECV304
ECV304 cells were plated in 96 well plates at a density of
5 × 104 cells/well cultured for 48 hours, the supernatant
was aspirated and untransfected U251, control-shRNA-
GFP U251 or SATB1-shRNA U251 cells were plated at a
density of 5 × 104 cells/well and cultured for 30 minutes.
The wells were washed twice with PBS to remove un-
attached cells 100 μl 25% rose Bengal solution was added,
incubated for 5 minutes, the supernatant was aspirated,
the wells were washed twice with PBS. 200 μl 95% etha-
nol/PBS (1:1) was added, incubated for 20 minutes and
absorbance was measured at 540 nm. Each assay was per-
formed in triplicate.
Adhesion assay
Cells were seeded in quadruplicate at a density of 1 × 104
cells/well in 96 well plates coated with 10 g/L BSA,
50 mg/L Matrigel, or 10 mg/L fibronectin (Fn), cultured
at 37°C for 60 minutes, and the MTT assay was per-
formed as previously described [26,27]. Each assay was
performed in triplicate.
Invasion assay
The invasion assays with cells were performed using
Transwell polycarbonate membrane inserts in 24-well
plates (Corning, Lowell, MA) following the manufac-
turer’s instructions. Briefly, the underside of each
polycarbonate microporous membrane was coated
with Matrigel (1:100) at 37°C for 5 minutes and
allowed to sit overnight. Then, 50 μl Matrigel (1:30)
and 200 μl sterile water were added to the upper
compartment at 37°C. After 2 days, 200 μl of the in-
vasion buffer [2 ml BSA (2%) + 38 ml RPMI 1640]
was added into the upper compartment and, 1 hour
later, the upper compartment fluid was aspirated.
Cells at a density of 5 × 104 cells/well were added
into the upper compartment, and 800 μl of the Fn
solution (10 μg/ml) was added into the lower com-
partment. The cells were allowed to migrate for 48
hours. The inserts were then fixed in 10% formalin,
stained with hematoxylin and eosin, and rinsed by
dipping in water. The cells on the upper surface of
the membrane were removed with a cotton bud. The
membranes were air-dried overnight, excised from
the insert, and mounted onto glass slides for micro-
scopic analysis. The migrated cells were counted at
high-power magnification (×40) from four randomly
selected fields. Each experiment was repeated three
times.In vitro angiogenesis assay
The test was performed using the In vitro Angiogenesis
Assay Kit (Chemicon International, Temecula, CA) fol-
lowing the manufacturer’s instructions. Briefly, 96-well
plates were coated with cold solution (50 μl/well of a so-
lution containing 900 μl of ECMatrix per 100 μl of 10×
diluent buffer), which was allowed to polymerize at
room temperature for about 60 minutes. Then, wells
were seeded with 100 μl of a 5 × 104 cells/ml suspension
of ECV304, ECV304 transiently transfected with pHK,
or ECV304 transiently transfected with SATB1-shRNA.
Tube formation was assessed after 12 hours.
Murine xenograft model
Male 4 to 6 week old BALB/c athymic nude mice were sub-
cutaneously injected with 2 × 106 untransfected U251,
control-shRNA-GFP U251 or SATB1-shRNA U251 cells.
Tumor diameters were measured at regular intervals with
digital calipers, and the tumor volume in mm3 was calcu-
lated using the formula: volume = (width)2 × length/2.
The animal experiments in this study were performed in
compliance with the guidelines of the Institute for
Medical School Institutes at Wuhan University and
Shanghai Jiao Tong University.
Data analysis
Statistical analyses and graphs were performed using the
Statistical Package for the Social Sciences (version 12.0,
for Windows) (SPSS, Chicago, IL, USA). Quantitative
values were expressed as mean ± SD. Statistical differ-
ences between groups were examined using the Fisher's
exact test. P-values less than 0.05 were considered statis-
tically significant.
Results
Immunohistochemical analysis of SATB1 expression in
human glioma and normal brain tissue
We examined the expression of SATB1 in 70 gliomas and
the normal brain tissues using immunohistochemistry.
The low expression of SATB1 were found in the normal
brain tissues (Figure 1A-C). In glioma tissues, brown posi-
tive staining was mostly homogeneously distributed within
the nucleolus, and in the high grade glioma tissues, SATB1
was expressed at increased levels compared to the low
grade glioma tissues (Figure 1D-O). Semi-quantitative
analysis indicated a significant increase in SATB1
expression in high grade gliomas and low grade gliomas
(P = 0.001, Figure 1P). The percentage of glioma tissues
that exhibited positive staining of SATB1 was 62.9%.
Expression of SATB1 in human glioma and normal brain
tissues as determined by RT-PCR and western blotting
The low expression of SATB1 mRNA and protein were
found in the three normal brain tissues and the
Figure 1 Immunohistochemical staining of SATB1 expression in human glioma and normal cerebral cortex tissue. A-C) normal cerebral
cortex tissue; D-F) glioma with WHO grade I; G-I) glioma with WHO grade II; J-L) glioma with WHO grade III; and M-O) glioma with WHO grade IV.
Serial sections of the same samples were used for hematoxylin and eosin (HE) staining. Magnified × 40 panels represented the white rectangles in
the × 10 panels. Scale bar = 100 μm. P) Semiquantitative analysis of SATB1 expression in high grade gliomas and low grade gliomas, P value
compares overall SATB1 expression in each group.
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in the high grade glioma samples compared with the low
grade glioma tissues (Figure 2A-B). Furthermore, the
RT-PCR and western blotting analysis showed that the
ratio of the high grade glioma tissues was more than that
of low grade glioma tissues (Figure 2C).Relationship between SATB1 expression, clinicopathologic
characteristics and MGMT promoter methylation
Correlations between the expression of SATB1 and vari-
ous clinicopathologic parameters and between the ex-
pression of SATB1 and MGMT promoter methylation
were listed in Table 1. The expression of SATB1 was sig-
nificantly related to the pathological grade of glioma
(P = 0.025). Overexpression of SATB1 was associated
with high pathological grade (WHO III-IV). The expres-
sion of SATB1 was significantly related to MGMT pro-
moter methylation (P = 0.000). However, no statistically
significant differences were identified between SATB1
expression in relation to age, sex, position or tumor size.Figure 2 RT-PCR and Western blotting analysis of SATB1 expression i
SATB1 RT-PCR (A) and Western blot (B). Lane 1, glioma with WHO grade IV
lane 4, glioma with WHO grade I; lane 5, normal brain tissue. (C) The ratio
dehydrogenase (GADPH)/β-actin showing increased SATB1 mRNA/proteinUnivariate and multivariate analyses of prognostic
variables in patients with glioma
The 5-year overall survival rates of patients with positive
and negative SATB1 expression were 18.2% (8/44) and
53.8% (14/26) respectively, and there was significant differ-
ence in 5-year overall survival rates (P = 0.002). The 5-year
survival rates of patients with positive and negative SATB1
expression in high grade glioma were 0/27 and 2/8 re-
spectively, and there was significant difference in 5-year
survival rates (P = 0.007). The 5-year survival rates of
patients with positive and negative SATB1 expression in
low grade glioma were 8/17 and 12/18 respectively, and
there was no significant difference in 5-year survival rates
(P = 0.241). Thus, future studies with larger sample sizes
should be done to confirm this trend. Patients showing
positive SATB1 expression in high grade glioma had a sig-
nificantly shorter overall survival period than those with
negative expression (P = 0.009, log-rank test; Figure 3).
Univariate Cox regression analysis also identified that clin-
ical variables including the pathological grade of glioma,
SATB1 expression and MGMT promoter methylationn human glioma and normal brain tissue. Representative images of
; lane 2, glioma with WHO grade III; lane 3, glioma with WHO grade II;
of SATB1 mRNA/protein expression to glyceraldehyde 3-phosphate
expression in high grade gliomas compared to low grade gliomas.
Table 1 Correlations between SATB1 expression,
clinicopathologic features and MGMT promoter
methylation in 70 cases of glioma
Clinicopathologic
variables
n SATB1 expression χ2 P-
valueNegative Positive
All cases 70 26 44
Age (years) 1.004 0.446
<45 27 12 15
≥45 43 14 29
Gender 0.388 0.566
Male 54 19 35
Female 16 7 9
Tumor size (cm) 0.227 0.795
<3 24 8 16
≥3 46 18 28
Tumor locus 0.946 0.393
Supratentorial 53 18 35
Infratentorial 17 8 9
Pathological grade 6.119 0.025
Low grade I-II 35 18 17
High grade III-IV 35 8 27
MGMT promoter 25.150 0.000
Unmethylation 45 7 38
Methylation 25 19 6
Figure 3 Kaplan-Meier survival analysis of glioma patients after
surgical resection. Samples with positive SATB1 expression (n = 44)
and negative SATB1 expression (n = 26) were analyzed. The survival
rate for patients in the SATB1 positive group (+) was significantly
lower than that for patients in the SLC22A18 negative group (−) (log
rank, P = 0.009).
Table 2 Univariate and multivariate analyses of different
prognostic factors in patients with gliomas
Variables Relative risk (95% CI) P-value
Univariate
Age 0.794 (0.413-1.275) 0.253
Sex 0.715 (0.362-1.389) 0.342
Tumor size 0.932 (0.579-2.486) 0.356
Tumor locus 0.683 (0.362-1.142) 0.182
Pathological grade 1.854 (1.143-3.045) 0.035
SATB1 0.448 (0.229-0.788) 0.009
MGMT methylation 0.224 (0.102-0.356) 0.004
Multivariate
Pathological grade 0.654 (0.453-1.026) 0.046
SATB1 0.446 (0.248-0.792) 0.015
MGMT methylation 0.412 (0.218-0.681) 0.012
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Furthermore, multivariate Cox regression analysis (For-
ward: LR) was performed to evaluate the potential of
SATB1 expression as an independent predictor for overall
survival of glioma patients. While other factors failed to
demonstrate independence, the correlation between the
pathological grade of glioma, SATB1 expression and
MGMT promoter methylation may play a role in predict-
ing overall survival in glioma (P = 0.046 and P = 0.015, P =
0.012, respectively, Table 2).
Association of the Ki67 index with SATB1 expression in
glioma
Ki67 immunostainings were widely variable in different
pathological grade gliomas and Ki67 were intensely
expressed in cell nuclei of glioma. The Ki67 indexes of
glioma tissues with positive SATB1 expression were
(49.12 ± 4.26)%, which were significantly higher than that
of glioma tissues without detectable SATB1 expression
(Table 3).
SATB1, c-Met, SLC22A18, caspase-3 and bcl-2 expression
in U251 cells and cell proliferation assay
The SATB1 mRNA and protein inhibition rate of
SATB1-shRNA U251 cells was 92% and 86% compared
with the untransfected U251 cells respectively, whereas
the control-shRNA-GFP U251 cells had not such change
(see Additional file 1: Figure S1A-D). The SATB1 pro-
tein inhibition rate of SATB1-shRNA U251 cells wasTable 3 Association between Ki67 index and SATB1
expression in glioma tissues
SATB1 n Ki67 index (%, mean ± SD) P
Positive 44 49.12 ± 4.26 0.000
Negative 26 10.34 ± 6.52
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immunofluoresence staining, whereas the control-
shRNA-GFP U251 cells had not such change (see
Additional file 2: Figure S2A and B). SATB1 was stained
red and located in nuclei of cells. The c-Met protein in-
hibition rate of SATB1-shRNA U251 cells was 61% com-
pared with the untransfected U251 cells, whereas the
control-shRNA-GFP U251 cells had not such change
(see Additional file 3: Figure S3A-B). Each group
revealed that in SATB1-shRNA U251 cells the expres-
sion of SLC22A18 and caspase-3 increased, whereas the
expression of bcl-2 decreased (see Additional file 3:
Figure S3A-B). SATB1-shRNA caused a statistically signi-
ficant reduction of cell viability to (29.5 ± 7.24)%, whereas
the control-shRNA-GFP U251 cells had not such change
(see Additional 4: Figure S4).Induction of apoptosis by SATB1-shRNA
To quantitate the SATB1-shRNA induced apoptotic cell
death in U251 cells, approximately 1× 106 U251 cells
were double stained with Annexin-V-FITC and propi-
dium iodide (PI) at different times post transfection.
Apoptotic cell death was detected from 24 hours and 48
hours after transfection (Figure 4A). FACS analysis iden-
tified significantly higher numbers of apoptotic cells inFigure 4 FACS Analysis of Annexin-V staining of U251 cells after tran
Percentages of apoptotic cells in U251 cells after transfection.SATB1-shRNA transfected U251 cells than untrans-
fected control cells (Figure 4B).Effects of SATB1-shRNA on U251 cell adhesion
The tumor cell lines showed different absorbance abil-
ities: untransfected U251 cells, 0.602 ± 0.007; control-
shRNA-GFP U251 cells, 0.593 ± 0.016; SATB1-shRNA
U251 cells, 0.262 ± 0.014 (Figure 5A). Suppressing
SATB1 expression had a clear inhibitory effect on the
adhesion of transfected U251 cells to the extracellular
matrix (ECM) [Matrigel and Fn] and to ECV304. The
percentages of adhesion to ECM were as follows:
untransfected U251 cells, (39.5 ± 2.24)% (Fn) and (90.2 ±
1.54)% (Matrigel); control-shRNA-GFP U251 cells, (38.9 ±
3.08)% (Fn) and (89.8 ± 1.56)% (Matrigel); SATB1-
shRNA U251 cells, (7.9 ± 3.25)% (Fn) and (36.2 ± 1.62)%
(Matrigel) (Figure 5B). Thus, the adhesion of U251-
SLC22A18 to ECV304 and to ECM cells was signifi-
cantly suppressed.Effects of SATB1-shRNA on U251 cell invasion
As shown in Figure 6A, for each 400× field under the
microscope, the number of migrated SATB1-shRNA
U251 cells was 243 ± 25, significantly lower than the
number of untransfected U251 cells (452 ± 18) and thesfection. (A) Representative FACS scatter plots of U251 cells. (B)
Figure 5 Effects of SATB1-shRNA on U251 cell adhesion. (A)
U251 cells adhesion to ECV304. (B) U251 cells adhesion to ECM (Fn
and Matrigel).
Figure 6 Effects of SATB1-shRNA on U251 cell invasion and
angiogenesis in vitro. (A) U251 cell invasion. (B) Angiogenesis
in vitro.
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there was little difference between untransfected U251
cells and the control-shRNA-GFP U251 cells.Effects of SATB1-shRNA on angiogenesis in vitro
As shown in Figure 6B, in vitro tube formation of
ECV304 cells transiently transfected with SATB1-
shRNA was 34 ± 5 per 100× field, which was significantly
lower compared with untransfected ECV304 (119 ± 10)
and ECV304 transiently transfected with control-shRNA-
GFP (122 ± 6). Moreover, there was little difference be-
tween untransfected ECV304 and ECV304 transiently
transfected with control-shRNA-GFP.Effects of the SATB1-shRNA on tumor growth in vivo
As shown in Figure 7, untransfected U251 and control-
shRNA-GFP U251 xenograft tumors formed and grew
rapidly. In contrast, SATB1-shRNA U251 xenograft
tumor formation was significantly delayed. At the end of
the experiment, the SATB1-shRNA U251 tumors were
significantly smaller than the tumors from untransfected
U251 and control-shRNA-GFP U251 cells.
Effects of the SATB1-shRNA on tumor angiogenesis in vivo
Tumor tissue from mice was excised and subjected to
immunohistochemical staining. As shown in Figure 8,
the microvascular density (MVD) values (per 200× field)
of subcutaneous tumors in untransfected U251, control-
shRNA-GFP U251, and SATB1-shRNA U251 cells were
18 ± 6, 17 ± 5, and 5 ± 3, respectively. These results indi-
cate that CD34-positive vessels were abundant in
Figure 7 Effects of SATB1-shRNA on tumor growth in vivo. (A) Subcutaneous tumor model. a and d, untransfected U251 cells group; b and e,
control-shRNA-GFP U251 cells group; c and f, SATB1-shRNA U251 cells group. (B) Tumor growth curves of each group over 28 days.
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http://www.translational-medicine.com/content/10/1/149subcutaneous tumors in the untransfected U251,
control-shRNA-GFP U251 cells, whereas vessel density
in both tumor types was significantly decreased in the
SATB1-shRNA U251 cells group.Figure 8 Effects of SATB1-shRNA on tumor angiogenesis in vivo. (A) E
group; b, control-shRNA-GFP U251 cells group; c, SATB1-shRNA U251 cellsDiscussion
Glioma is one of the most aggressive human tumors and
the prognosis for glioma patients is bleak, even with
improved diagnosis and composite therapy [28].xpression of CD34 in subcutaneous tumors. a, untransfected U251 cells
group. (B) The MVD values (per 200× field) of subcutaneous tumors.
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markers is invaluable for the clinician to evaluate
patients and to aid in tumor control, and studies of the
underlying molecular mechanisms involved in glioma
formation and progression provide tremendous oppor-
tunities to identify molecules which may provide novel
potential drug design targets for the treatment of brain
tumors. Using molecular analysis, loss of heterozygosity
has been observed on several chromosomes in patients
with glioma. Many of these chromosomal segments con-
tain known tumor suppressor genes [26,29], such as p53
on 17p and SLC22A18 on 11p15.5. Mutations and over-
expression of several genes, including c-Met, PDGF and
c-myc, have been identified in glioma patients [30,31].
SATB1 is a tissue-specific nuclear matrix-attachment-
DNA-binding protein, which is located on chromosome
3p23. The investigations of SATB1 were carried out
mainly in immune cells in the past. SATB1 plays an im-
portant role in the development and maturation of
CD8SP T cells [9]. It is a notable organizer of thymocyte
chromatin which controls gene expression and gene re-
combination in developing thymocytes [32]. SATB1 has
recently attracted considerable attention due to its high
expression in tumor tissues of a variety of malignancies
[9-13], which suggest a crucial role in promoting tumor
growth, invasion and metastasis, and may also have a
potential value of being a candidate for cancer therapy
[14]. SATB1 can regulate the expression of other genes
by many mechanisms [8,33-36]. Recently, Han et al.
[15]. have discovered that SATB1 protein is expressed in
poorly differentiated infiltrating tumor, but is absent in
normal tissue. 1,318 breast cancer specimens were ana-
lyzed in the study and revealed a correlation between
higher SATB1 expression levels and shorter overall sur-
vival times. They also revealed that a knockdown of
SATB1 in highly aggressive (MDA-MB-231) cancer cells
altered the expression of 1,000 genes, reversing tumori-
genesis and inhibiting tumor growth and metastasis
in vivo. These observations indicate that SATB1 repro-
grams chromatin organization and the transcription pro-
files of tumors to promote growth, spreading and
metastasis; however, SATB1 expression in glioma and
the relationship with glioma progression has not previ-
ously been investigated in humans.
In our study, we demonstrated that of 70 tumors, 44
(62.9%) were positive for SATB1 expression. The 5-year
overall survival rates of patients with positive and negative
SATB1 expression were 18.2% (8/44) and 53.8% (14/26) re-
spectively, and there was significant difference in 5-year
overall survival rates. The 5-year survival rates of patients
with positive and negative SATB1 expression in high grade
glioma were 0/27 and 2/6 respectively, and there was sig-
nificant difference in 5-year survival rates. Our results
showed that SATB1 expression was significantly associatedwith a high histological grade and with poor survival in uni-
variate and multivariate analyses. Correlation analysis
showed the expression of SATB1 is correlated with MGMT
promoter methylation which is a key prognostic factor and
can predict treatment response in glioma [37,38]. In our
Cox regression analysis, MGMT promoter methylation was
considered as an independent prognostic factor. Cox multi-
variable analysis showed that SATB1 expression correlated
with poor prognosis in patients with gliomas and was an in-
dependent prognostic factor. SATB1 expression was also
positively correlated with Ki67 expression in glioma tissue.
SATB1 shRNA expression vectors could efficiently induce
the expression of SLC22A18 protein and increase the
caspase-3 protein, and inhibit the expression of SATB1, c-
Met and bcl-2 protein and the growth, invasion, metastasis
and angiogenesis of U251 cells and, induced apoptosis
in vitro. Furthermore, the tumor growth of U251 cells
expressing SATB1 shRNA were inhibited in vivo, and
immunohistochemical analyses of tumor sections revealed
a decreased vessel density in the animals where shRNA
against SATB1 were expressed. Our results revealed that a
knockdown of SATB1 in highly aggressive glioma U251
cells could alter the expression of c-Met, SLC22A18,
caspase-3 and bcl-2 protein, reversing tumorigenesis, inhi-
biting tumor growth, invasion and angiogenesis, and indu-
cing apoptosis. These observations indicate that SATB1
may reprogram chromatin organization and the transcrip-
tion profiles of tumors to promote growth and invasion.
These results indicated that SATB1 may have an important
role as a positive regulator of glioma development and
progression.
Conclusions
Collectively, our findings indicated for the first time that
SATB1 was overexpressed in human glioma, and SATB1
expression in human glioma was associated with clinico-
pathological factors and prognosis. The high SATB1 ex-
pression, directly contributing to tumor development
and progression, might be a candidate independent
prognostic marker for predicting the outcome of human
glioma. Furthermore, the present study demonstrated
that RNA interference of SATB1 successfully inhibited
the expression of SATB1 protein and mRNA, the
growth, adhesion, invasion, metastasis and angiogenesis
in vitro and tumor growth and angiogenesis in vivo,
which might be the result of reducing expression of
SATB1, c-Met and bcl-2 protein and increasing the ex-
pression of SLC22A18 and caspase-3.
Additional files
Additional file 1: Figure S1. RT-PCR and Western blotting analysis of
SATB1 expression inhibited by shRNA and the inhibition rate.
Representative images of SATB1 RT-PCR (A) and Western blot (C). The
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http://www.translational-medicine.com/content/10/1/149SATB1 mRNA expression inhibition rate of SATB1-shRNA (B) and the
SATB1 protein expression inhibition rate of SATB1-shRNA (D) in U251
cells. Lane 1, untransfected U251 cells; lane 2, control-shRNA-GFP U251
cells; lane 3, SATB1-shRNA U251 cells.
Additional file 2: Figure S2. Immunofluoresence staining analysis of
SATB1 expression inhibited by shRNA and the inhibition rate.
Representative images of the untransfected U251 cells (A), control-
shRNA-GFP U251 cells (B), SATB1-shRNA U251 cells (C), and the inhibition
rate of untransfected U251 cells, control-shRNA-GFP U251 cells and
SATB1-shRNA U251 cells (D). Nuclei were counterstained using DAPI.
Scale bar = 25 μm.
Additional file 3: Figure S3. Western blotting analysis of c-Met,
SLC22A18, caspase-3 and bcl-2 protein expression. (A) Representative
images of western blotting analysis of c-Met, SLC22A18, caspase-3 and
bcl-2 expression. (B) Level of the c-Met, SLC22A18, caspase-3 and bcl-2
protein expression in U251 cells. Lane 1, untransfected U251 cells; lane 2,
control-shRNA-GFP U251 cells; lane 3, SATB1-shRNA U251 cells.
Additional file 4: Figure S4. Cytotoxic effect of SATB1-shRNA in U251
cells. The untransfected U251 cells, control-shRNA-GFP U251 cells and
SATB1-shRNA U251 cells were cultured in plastic 96-well plates and
quantified using the MTT assay.
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